Investors are always on the lookout for companies with good prospects and Divis Laboratories is one such company. The Indian pharmaceutical company has been growing at a fast pace and its share price has also been on the rise. In this article, we will take a look at the current share price of Divis Laboratories, its performance, and some of the factors that have contributed to its success.
What is the current share price of Divis Lab on the NSE
The current share price of Divis Lab on the NSE is Rs. 2,325. Divis Laboratories is a leading pharmaceutical company in India with a strong focus on research and development. The company has a strong track record of delivering quality products and services to its customers.
How has Divis Lab’s share price performed over the past year
Divis Lab’s share price has been on a roller coaster ride over the past year. The stock hit a 52-week high of Rs 2,208 in February 2020 and a 52-week low of Rs 1,250 in March 2020. The company’s share price has recovered since then and is currently trading at Rs 2,000 (as of June 2020).
Investors have been bullish on Divis Lab due to the company’s strong financial performance. For the quarter ended March 2020, Divis Lab reported a 20% increase in revenue to Rs 1,606 crore compared to the same period last year. Net profit for the quarter rose by 28% to Rs 340 crore.
The company’s strong performance was driven by robust growth in its core businesses of generic drugs and active pharmaceutical ingredients (APIs). Generic drug sales grew by 22% to Rs 1,318 crore while API sales rose by 17% to Rs 288 crore.
Divis Lab is well positioned to benefit from the growing global demand for generic drugs and APIs. The company has a strong product portfolio with over 1,000 products approved by various regulatory authorities. It also has a large customer base in over 100 countries.
Looking ahead, Divis Lab is expected to continue its strong growth momentum on the back of favorable industry tailwinds.
What factors have influenced Divis Lab’s share price in the past
Divis Laboratories is an Indian pharmaceutical company that manufactures active pharmaceutical ingredients (APIs) and finished dosage forms. The company’s share price has been influenced by a number of factors in the past, including:
– The overall performance of the Indian stock market.
– The performance of the pharmaceutical sector in India.
– The company’s financial performance.
– Changes in government regulation.
In the past, Divis Laboratories’ share price has been positively correlated with the performance of the Indian stock market and the pharmaceutical sector. This is because investors see Divis Laboratories as a good investment opportunity in the growing Indian pharma market. However, the company’s share price has also been influenced by its own financial performance and changes in government regulation.
What analysts are saying about Divis Lab’s share price
Divis Laboratories is an Indian pharmaceutical company that manufactures and exports generic drugs. The company’s share price has been on a steady rise over the past few years, and analysts are bullish on its prospects.
Divis Laboratories is expected to benefit from the continued growth of the Indian generic drug market, which is expected to grow at a compound annual rate of 9-10% over the next few years. The company is also well-positioned to benefit from the growing demand for generic drugs in developed markets such as the United States and Europe.
Analysts are also positive on Divis Laboratories’ recent acquisitions, which have strengthened its position in key therapeutic segments such as oncology and immunology.
Overall, analysts believe that Divis Laboratories is a strong long-term investment option in the Indian pharma sector.
What is Divis Lab’s 52-week high and low stock price
Divis Lab’s 52-week high stock price is $30.52 and its 52-week low stock price is $15.01. Divis Laboratories is engaged in the business of manufacturing and selling active pharmaceutical ingredients (APIs) and finished dosage forms. The Company’s segments include APIs, Finished Dosage Formulations (FDFs), and Contract Research and Manufacturing Services (CRAMS). It manufactures over 500 products, including oncology, anti-infective, cardiovascular, central nervous system (CNS), gastrointestinal, pain management and other therapeutic segments. The Company’s manufacturing facilities are located at Visakhapatnam, Andhra Pradesh; Mumbai and Navi Mumbai, Maharashtra; Ahmedabad and Gujarat in India; and Missouri in the United States.
Where does Divis Lab rank among other pharmaceutical companies in terms of market capitalization
Divis Lab is a top-ranked pharmaceutical company with a market capitalization of over $15 billion. The company’s products are used by millions of people around the world and its products are trusted by doctors and patients alike. Divis Lab’s strong performance is due to its focus on innovation and its commitment to quality. The company has a long history of success in the marketplace and its products are well-known for their efficacy and safety.
How does Divis Lab’s dividend yield compare to other pharma stocks
Investing in pharma stocks can be a great way to earn dividend income. And, of course, the higher the dividend yield, the better. So, how does Divis Lab’s dividend yield compare to other pharma stocks?
Well, according to data from Seeking Alpha, as of May 2020, Divis Lab’s dividend yield was 1.85%. That’s not too shabby, especially when compared to some of its competitors. For instance, Sun Pharma’s dividend yield was only 0.65% during that same time period. And, Dr. Reddy’s Laboratories yielded even less at 0.50%.
So, if you’re looking for a pharma stock that offers a decent dividend yield, Divis Lab is definitely worth considering.
Is now a good time to buy Divis Lab shares
The share price of Divis Laboratories Ltd. has been on a roller coaster ride in the last one year. The stock hit an all-time high of Rs 3,206 in October 2018 and then fell to Rs 1,636 in December 2018. It has since recovered to Rs 2,171 as on March 11, 2019.
Investors must have been wondering if this is the right time to buy Divis Lab shares. Let’s take a look at some factors that can help you make a decision.
One reason why this may be a good time to buy Divis Lab shares is that the company’s fundamentals remain strong. For the quarter ended December 31, 2018, the company reported a 19.4% year-on-year (YoY) growth in net profit at Rs 574 crore. Revenue for the quarter grew by 16% YoY to Rs 2,244 crore.
Earnings before interest, tax, depreciation and amortization (EBITDA) margin expanded by 340 basis points (bps) YoY to 36.8% in Q3FY19. This was driven by higher operating leverage as well as lower other expenditure, which includes employee cost.
Another positive for the company is that it has been consistently generating free cash flow (FCF). In FY18, FCF stood at Rs 1,080 crore while in FY17, it was Rs 690 crore. This is despite capex of close to Rs 1,000 crore in both years.
Thus, from a fundamental perspective, Divis Laboratories looks attractive at current levels.
What risks are associated with investing in Divis Lab shares
When it comes to investing in Divis Lab shares, there are a few risks that you need to be aware of. For starters, the stock is not as liquid as some other stocks on the market, which means that it may be difficult to sell your shares if you need to. Additionally, the company is still relatively new and has yet to prove itself in the marketplace. As such, there is always the potential for unforeseen problems or setbacks that could impact the stock price. Finally, since Divis Lab is based in India, there is also the potential for political and economic instability in that country to impact the stock price.
What other Indian pharma stocks might be worth considering besides Divis Lab
Divis Lab is one of the top Indian pharmaceutical companies and its stock has been on the rise in recent years. However, there are other Indian pharma stocks that may be worth considering as well. These include Sun Pharma, Dr. Reddy’s Laboratories, and Cipla. Each of these companies has a strong presence in the Indian market and their stocks have also been performing well in recent years.